Aberrant CD3 Expression in a Relapsed Plasma Cell Neoplasm.

J Pathol Transl Med

Department of Pathology, Dankook University College of Medicine, Cheonan, Korea.

Published: May 2018

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964284PMC
http://dx.doi.org/10.4132/jptm.2017.09.05DOI Listing

Publication Analysis

Top Keywords

aberrant cd3
4
cd3 expression
4
expression relapsed
4
relapsed plasma
4
plasma cell
4
cell neoplasm
4
aberrant
1
expression
1
relapsed
1
plasma
1

Similar Publications

Mepolizumab in patients with lymphoid variant hypereosinophilic syndrome: a multi-center prospective study.

J Allergy Clin Immunol

January 2025

Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium.

Background: Hypereosinophilic syndrome (HES) is characterized by blood and tissue hypereosinophilia causing organ damage and/or dysfunction. Mepolizumab, an anti-IL-5 antibody, has recently been approved in this indication. In lymphoid variant (L-)HES, eosinophil expansion is driven by IL-5-producing clonal CD3CD4 T cells.

View Article and Find Full Text PDF

This report describes a rare case of relapsed multiple myeloma in the gastrointestinal tract with aberrant CD3 expression. Upon admission for acute renal failure, the patient had abnormal computed tomography scan findings of the abdomen and pelvis. Subsequent colonoscopy found numerous polyps and masses.

View Article and Find Full Text PDF

The clinical and immunophenotypic attributes of reactive γδ T-cell expansions are less well characterized than their malignant counterparts, which can pose diagnostic challenges. This study aims to investigate the characteristics and long-term clinical outcomes of reactive γδ T-cell expansions. A retrospective review was performed to identify patients with expanded γδ T-cell population (>15% of T-cells) by flow cytometry in peripheral blood and/or bone marrow specimens over a 17-year period.

View Article and Find Full Text PDF

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the main chronic liver diseases. However, the roles of mitochondrial carnitine palmitoyl transferase-II (CPT-II) downregulation and liver cancer stem cell (LCSC) activation remain to be identified.

Aim: To investigate the dynamic alterations in CPT-II inactivity and LCSC activation during the malignant progression of MAFLD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!